Companies › Cibus Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Gastroenterology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CBT-248 | – | Phase 1 | Chronic Pancreatitis | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07905053 | CBT-248 | Phase 1 | Chronic Pancreatitis | Gastroenterology | May 2027 |
Cash of $20m on 2026-06-30; operating cash outflow about $42m a year; runway about 6 months at that burn, to Dec 2026
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.